The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for blockbuster treatments and impressive returns is clear, the linked risks are also notable. Many of thes… Read More